Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ceftriaxone Sodium

FDA-approved product (injectable, injection), marketed as Ceftriaxone, Ceftriaxone And Dextrose In Duplex Container, Ceftriaxone In Plastic Container and 3 more.

Registered studies
50+
Lab records
68
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ceftriaxone Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Gonorrhea
  • Infection
  • Infectious meningitis
  • Otitis media
  • Pelvic Inflammatory Disease
  • Respiratory tract infectious disorder
  • Sepsis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Third-generation cephalosporins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DD04; WHO ATC J01DD54

Repurposing investigation

Ceftriaxone Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA82.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae35.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis56.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 8 of 8 lab records
  • E. coli: measured active in 4 of 4 lab records
  • K. pneumoniae: measured active in 26 of 56 lab records
Open Ceftriaxone Sodium in ChEMBL Registered studies below
Show the 68 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ceftriaxone Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia

    NCT00111644 · start 2005-03

    Registered record
    Registry ID
    NCT00111644
    Conditions
    Pneumonia, Bacterial
    Interventions
    Ceftriaxone; beta-lactam; beta-lactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-03
    Completion
    2007-01
    Enrolment
    302

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia, Bacterial
    InterventionCeftriaxone; beta-lactam; beta-lactam
    PhasePhase 2
    Registry statusCompleted

  • Ceftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal Pneumonia

    NCT00429975 · start 2004-08

    Registered record
    Registry ID
    NCT00429975
    Conditions
    Pneumonia, Pneumococcal
    Interventions
    levofloxacin; ceftriaxone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2004-08
    Completion
    2005-09
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia, Pneumococcal
    Interventionlevofloxacin; ceftriaxone
    PhasePhase 4
    Registry statusTerminated

  • Cefepime vs. Ceftriaxone to Treat Nursing Home-Acquired Pneumonia

    NCT00358202 · start 2002-03

    Registered record
    Registry ID
    NCT00358202
    Conditions
    Pneumonia
    Interventions
    cefepime; ceftriaxone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-03
    Completion
    2006-04
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    Interventioncefepime; ceftriaxone
    PhasePhase 4
    Registry statusCompleted

  • Brain Imaging and Retreatment Study of Persistent Lyme Disease

    NCT00037479 · start 1999-12

    Registered record
    Registry ID
    NCT00037479
    Conditions
    Lyme Disease; Lyme Neuroborreliosis
    Interventions
    ceftriaxone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-12
    Completion
    Not recorded
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLyme Disease; Lyme Neuroborreliosis
    Interventionceftriaxone
    PhasePhase 2
    Registry statusCompleted

  • VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy

    NCT00004216 · start 1999-08

    Registered record
    Registry ID
    NCT00004216
    Conditions
    Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    salmonella VNP20009; cefixime; ceftriaxone sodium; ciprofloxacin; trimethoprim-sulfamethoxazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1999-08
    Completion
    2008-01
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnspecified Adult Solid Tumor, Protocol Specific
    Interventionsalmonella VNP20009; cefixime; ceftriaxone sodium; ciprofloxacin +1 more
    PhasePhase 1
    Registry statusCompleted